The peer reviewed results published today in the Journal of Urology found that Aureon Laboratories‘ Prostate Px+ test is twice as effective as other tools currently available at identifying which patients classified as intermediate-risk have high-risk, life-threatening cancer.
The Prostate Px+ test analyzes tumor biopsy samples to predict patient outcome at the time of diagnosis, helping physicians make more informed treatment decisions. According to Aureon CEO Vijay Aggarwal, the Px+ system is “a first application of this type of technology to personalized medicine.”
Today, more than 85% of all newly diagnosed patients are considered low- or intermediate-risk by American Urological Association guidelines. Noteworthy is the fact that two patients in the same risk group, with similar clinical features, can have very different outcomes. For this reason, it is important for patients to understand as much about their disease as possible. Knowing their individual risk allows patients, with their physicians, to make more informed treatment decisions. Prostate cancer, which is the most commonly diagnosed non-skin cancer among men, kills approximately 29,000 men each year.
“We are very excited about this article because it provides important peer-reviewed credibility for our biopsy-based test,” says Aggarwal. Aureon Laboratories of Yonkers, NY, develops predictive clinical tests for cancer care.
Related video: Dr. Vijay Aggarwal, CEO of Aureon Laboratories, discusses the Journal of Urology peer review.
